Advair HFA in Healthy and HAPE Predisposed Subjects

NCT ID: NCT06040268

Last Updated: 2025-09-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-12
• Study Completion Date: 2026-12-15

Brief Summary

The current protocol is composed of two studies. The first study is designed to carefully evaluate the safety of high-dose salmeterol/fluticasone (Advair HFA) versus placebo (hydrofluoroalkane, HFA) administration over 7 days, as well as the efficacy of the study drug to increase exercise performance, in healthy individuals exercising under hypoxic, simulated high-altitude conditions (Phase 1/2a study). The second study will examine sensitive measures of cardiopulmonary function using invasive cardiopulmonary testing, in both HAPE-sensitive and HAPE-resistant individuals, to assess the potential efficacy of salmeterol/fluticasone to prevent pulmonary edema and to enhance exercise capacity (Phase 2a) in these individuals.

Detailed Description

Both Study 1 and Study 2 are double-blinded, randomized, placebo-controlled, two-period, crossover studies.

Study 1 (Phase 1/2a) is a Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover study examining safety and efficacy in healthy subjects dosed with salmeterol/fluticasone 126mcg/270mcg twice daily vs. placebo, for 7 days. Subjects will exercise under hypoxic conditions one time during each study period with the primary efficacy outcome being maximal oxygen uptake (VO2max), and secondary outcomes of arterial partial pressure of oxygen (PaO2), alveolar-arterial oxygen (Aa) gradient, and blood lactate levels. Continuous cardiac monitoring will occur during study drug dosing and for 5 days after drug discontinuation. ECGs and safety lab tests will be assessed at key intervals during drug dosing. A pause in enrollment will occur for a planned data and safety monitoring board (DSMB) safety analysis after four subjects have completed Study 1. There will also be a full review of safety data once Study 1 is complete prior to initiating Study 2.

Study 2 (Phase 2a) is a Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover study examining efficacy and safety in both healthy (HAPE-resistant) and HAPE-susceptible subjects dosed with salmeterol/fluticasone 126mcg/270mcg twice daily. Subjects will take study drug for two days prior to hypoxic exercise testing in each period of this study, then discontinue study drug when the exercise is completed. Efficacy assessments will include VO2 max (primary outcome), right heart catheter measurements, PaO2, A-a gradients, and blood lactate.

For both studies, investigators and subjects will be blinded to assignment group (order of study drug vs. placebo).

Conditions

Altitude Edema

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Advair HFA (salmeterol 126 ug/fluticasone 270 ug) twice daily for up to 7 days

Participants will inhale salmeterol 126 ug and fluticasone 270 ug twice daily for up to 7 days

Group Type: EXPERIMENTAL

Advair HFA

Intervention Type: DRUG

6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily

Placebo

Participants will inhale placebo (same puff number) twice daily for up to 7 days

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

HFA134a inhaler

Interventions

Advair HFA

6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily

Intervention Type: DRUG

Placebo

HFA134a inhaler

Intervention Type: DRUG

Other Intervention Names

salmeterol and fluticasone in hydrofluoroalkane (HFA) propellant; HFA134a (hydrofluoroalkane 134a, same propellant as in Advair HFA)

Eligibility Criteria

Inclusion Criteria

• Written informed consent signed prior to entry into the study.
• Male or female age 18-50 years of age
• BMI ≥ 20 and < 35 kg/m2
• Agreement to comply with the study-required interventions and treatment during the full duration of the study.
• In good health as determined by screening medical history, physical examination, vital signs (blood pressure, heart rate, respiratory rate and temperature), clinical laboratory tests (CBC, protime (PT) (INR)/partial thromboplastin time (PTT), thyroid stimulating hormone (TSH), Total Bilirubin, blood chemistries, urine drug screening), and a resting 12-lead Electrocardiogram with a 10 second rhythm strip.
• Adequate peripheral venous access for IV insertion and blood sample collection (assessments will be made prior to undergoing further assessments).
• HAPE-susceptible individuals (Study 2 only) must have had a medically documented (hospital admission or emergency room visit) HAPE episode characterized by noncardiogenic pulmonary edema and hypoxemia that occurred during high altitude travel in Colorado and must reside below 3,000 feet (unacclimatized individuals; non-Colorado residents).
• HAPE-resistant individuals (Study 2 only) will have had no evidence of HAPE during high altitude travel in Colorado, and must reside below 3,000 feet (unacclimatized; often being travel partners of HAPE-susceptible subjects).
• Healthy controls (Study 1 only) will all be Colorado residents.

Exclusion Criteria

• Currently participating in or has been enrolled in another clinical trial within the last 30 days (observational studies are acceptable).
• Donation of any blood or plasma in the last month, or donation of > 500 milliliters (ml) of blood within the 3 months preceding study drug administration.
• Female subjects of childbearing potential with positive serum pregnancy (beta human chorionic gonadotropin) test, who are breastfeeding, plan to become pregnant during the study, or decline to either be abstinent or use highly effective birth control if they have sexual intercourse with a male partner (ie, oral contraceptives; contraceptive patches, implants, injections, and rings; intrauterine devices - both hormonally-impregnated and untreated devices) throughout the study and for at least 1 month after study completion;
• Known history of impaired liver function
• Clinically significant laboratory abnormalities (one retest is allowed at the discretion of the Investigator and Medical Monitor), defined as:

• Impaired renal function as estimated glomerular filtration rate < 60 mL/min/1.73 m2) as estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening.(81)
• Serum Potassium < 3.2 millimolar (mM)
• aspartate aminotransferase (AST) or alanine transaminase (ALT) > 2x upper reference limit
• international normalized ratio (INR) > 1.5
• Fasting serum triglycerides > 500 mg/dL (lipemic serum affects assays)
• TSH < 0.5 or > 5 milliunits/Liter (mU/L)
• Hemoglobin < 12.0 g/dL
• Bilirubin > 2, unless consistent with Gilbert's disorder (indirect bilirubinemia)
• Platelet count < 100,000/µL
• Any other abnormality deemed by the Investigator to exceed normal safety limits for this study or exclude subject participation.
• Cardiovascular conditions:

• Clinically significant abnormal electrocardiogram at screening:

▪ Clinically significant abnormal ECG results including but not limited to complete left or right bundle branch block; other ventricular conduction block (except for incomplete bundle branch blocks, with a Q to R to S (QRS) duration < 0.12 sec) ; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two or more premature ventricular contractions (PVC) in a row; pattern of (S wave to T wave) ST segment elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator

• Any history of congenital or acquired long QT syndrome
• Any history of uncorrected re-entrant supraventricular tachycardia, atrial fibrillation, sinus tachycardia (> 100 bpm at rest), or ventricular tachycardia.
• Evidence of conduction abnormality including QTc prolongation on ECG, defined as > 450 msec for men and > 470 msec for women
• Unstable angina pectoris, history of myocardial infarction (MI), transient ischemic attack (TIA) or stroke within 3 months prior to screening, or subjects who have ever undergone percutaneous coronary intervention or a coronary artery bypass or who are due to undergo these procedures at the time of screening, as evidence of atherosclerotic cardiovascular disease (ASCVD).
• New York Heart Association Functional Class I-IV congestive heart failure (any congestive heart failure)
• Use of any blood thinner (e.g. novel oral anticoagulant, coumadin/warfarin). Use of aspirin is acceptable for study and will not need to be discontinued prior to involvement in the study. Use of a P2Y12 inhibitor (such as clopidogrel) is also not permitted due to bleeding risks.
• Use of any phosphodiesterase-5 inhibitors (as prescribed medications or obtained by other means) such as sildenafil, tadalafil, or vardenafil (as they may enhance hypoxic exercise performance)
• Infectious conditions:

o Active Coronavirus Disease 2019 (COVID-19) or any viral upper respiratory infection suspected by symptoms and/or confirmed by nasal swab polymerase chain reaction (PCR) or rapid antigen within the past 30 days. Subjects will be screened for COVID-19 at study entry by nasal swab antigen test on day 0 regardless of symptoms. A subject with recent COVID-19 will be allowed to participate provided that the diagnosis was made more than 30 days previously, COVID-related symptoms have been absent for 20 or more days, and an antigen test on day 0 is negative.

• Concomitant Medications:

• Nonselective beta-blockers including propranolol, carvedilol, and labetalol (due to antagonization of beta-2 agonist effects)
• Use of any inhaled or oral beta-2 receptor agonists, or oral theophylline
• Non-potassium sparing diuretics (due to hypokalemia risks)
• The use of any medication known to be a strong inhibitor or strong inducer of cytochrome P (CYP) 3A4 or 3A5 enzymes (cytochrome P450 isoenzymes) that metabolize salmeterol.(66) Also, any medication that has been reported to have a major or moderate interaction with salmeterol or fluticasone(82)
• Use of monoamine oxidase inhibitors or tricyclic antidepressants within 2 weeks of screening
• Prescription amphetamines or other sympathetic stimulants used for disorders such as narcolepsy, somnolence, or attention deficit disorder
• History of claustrophobia or post traumatic stress disorder that would limit use of gas breathing masks or mouthpieces.
• Essential tremor limiting handwriting, or any tremor requiring medication.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

United States Department of Defense

FED

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

James P Maloney, MD

Role: PRINCIPAL_INVESTIGATOR

Univ. of Colorado, Denver

Locations

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

James P Maloney, MD

Role: CONTACT

james.maloney@ucdenver.edu

3037246072

Facility Contacts

james maloney, MD

Role: primary

james.maloney@cuanschutz.edu

303-724-6072

Saedie Hawbaker, MPH

Role: backup

saedie.hawbaker@cuanschutz.edu

3037246072

Other Identifiers

W81WXH2290024

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

23-0463

Identifier Type: -

Identifier Source: org_study_id